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Abstract. Uterine leiomyomas are benign smooth muscle cell 
tumors that originate from the myometrium. In this study we 
focus on dysregulated chaperones associated with cell prolif-
eration and apoptosis. Paired tissue samples of 15 leiomyomas 
and adjacent myometria were obtained and analyzed by 
two-dimensional gel electrophoresis (2-DE). Mass spectrom-
etry was used for protein identification and western blotting for 
2-DE data validation. The values of 6 chaperones were found 
to be significantly different in the leiomyoma when compared 
with the myometrium. A total of 4 proteins were upregulated in 
the leiomyoma and 2 proteins were downregulated. Calreticulin 
and 78 kDa glucose-regulated protein were further validated 
by western blotting because the first is considered a marker of 
cell proliferation, while the second protects against apoptotic 
cell death. In addition, we also validated the two downregu-
lated proteins heat shock protein β-1 and heat shock 70 kDa 
protein 1A. Our study shows the existence of a dysregulation 
of chaperone proteins associated with leiomyoma development. 
Functional studies are needed to ascertain the role of these 
chaperones in the leiomyoma. This may be crucial for the 
further development of specific inhibitors against the activity 
of these proteins in order to block the growth of the leiomyoma.
Introduction
Uterine leiomyomas are benign smooth muscle cell tumors 
originating from the myometrium. These tumors can occur in 
70‑80% of women and are the first gynecological reason why 
women undergo hysterectomy (1). It has been ascertained that 
leiomyoma growth is strongly dependent on steroids, growth 
factors, transforming growth factor-β (TGF-β)/Smad, wing-
less-type (Wnt)/β-catenin, retinoic acid, and vitamin D (2). We 
also established that protein expression is associated hormone 
secretion (3).
Molecular evidence supports a role for genes, involved 
in extracellular matrix (ECM) production, in tumor volume 
expansion (4). Genetic alterations are considered insufficient 
drivers of tumor development, and additional complex signaling 
pathway (p38 MAPK pathway, VEGF signaling pathway, UPR 
pathway) alterations may be crucial (2). Heat shock proteins 
have often been associated with tumor progression through 
their ability to evade apoptosis and senescence (5). HSP90 plays 
an important role in estradiol signaling, chaperoned unbound 
estrogen receptors (ER). This protein helps in molecular 
trafficking inside the nucleus, leading the modulation of the 
transcriptional activities (6,7) of target genes correlated with 
tumor development.
Several external factors, including proteins, can induce 
alterations in the mechanotransduction signal from ECM 
via the transmembrane (8) receptor to the interior of the cell, 
leading to cell migration (9), metabolic dysregulation (10), 
proliferation and growth.
The objective of our study was to individuate dysregulated 
chaperonins with possible involvement in leiomyoma patho-
biology.
Materials and methods
General. Tissue samples were obtained from 15 premenopausal 
patients who underwent hysterectomy for symptomatic uterine 
leiomyomas. All procedures conformed with the Declaration 
of Helsinki and were approved by the Review Board of the 
Institute for Maternal and Child Health-IRCCS ‘Burlo 
Garofolo’ (Trieste, Italy). All involved subjects signed a written 
informed consent. The median age of patients was 45 years, 
with a minimum of 36 and a maximum of 48 years.
Tissue samples. Two samples were collected from each patient: 
One from the central area of the leiomyoma and one from the 
unaffected myometrium. All leiomyomas were confirmed 
histologically as benign ordinary leiomyomas. Samples were 
stored at ‑80˚C until proteomic analysis was performed.
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Two‑dimensional gel electrophoresis (2‑DE) and spot 
quantification. 2-DE analysis was performed as previously 
described (11). Briefly, clean samples of leiomyoma and 
myometrium (200 mg each) were homogenized in 1.2 ml of 
dissolution TUC buffer [7 M urea, 2 M thiourea, 4% CHAPS, 
40 mM Tris, 65 mM DTT and 0.24% Bio-Lyte (3-10)] with 
a protease inhibitor mix (2 mM PMSF, 1 mM benzamidine, 
1 mM EDTA, 1 mM NaF). After vortex, the solutions 
were centrifuged at 10,000 x g at 4˚C for 30 min and the 
protein content of the supernatant was determined using the 
Bradford assay. For the 2-DE analysis, 1,000 µg of proteins 
from each sample were used. Isoelectric focusing (IEF) was 
performed by using NL IPG Readystrips, 18-cm pH 3-10 in 
a Protean IEF cell (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA) set to 170,000 Vh. After IEF, the IPG strips were 
equilibrated for 20 min in equilibration buffer (6 M urea, 2% 
SDS, 50 mM Tris-HCl pH 8.8, 30% glycerol, and 1% DTT) 
and in equilibration buffer containing 4% iodoacetamide 
instead of DTT. For the second dimension, equilibrated 
IPG strips were transferred onto a 12% SDS-PAGE and 
were run on Protean II XL Cell (200 V constant voltage) 
until the bromophenol blue reached the bottom of the gel. 
After the second dimension, gels were stained with colloidal 
Coomassie Blue, and excess dye was removed with distilled 
water. Two experimental replicates were performed per 
sample.
Molecular masses were determined by precision protein 
standard markers (Bio-Rad Laboratories, Inc.). 2-DE gels were 
scanned with a Molecular Imager PharosFX system (Bio-Rad 
Laboratories, Inc.). The quantitative analysis of the spots was 
conducted out using the ProteomeWeaver 4 program (Bio-Rad 
Laboratories, Inc.).
Differences were considered to be signif icant 
when the ratio of the mean percentage relative volume 
(%V=Vsingle spot/Vtotal spot) was 1.5-fold for upregulated 
and 0.6-fold for downregulated proteins, and satisfied the 
non-parametric Wilcoxon signed-rank test for matched 
samples (P<0.05). Fold-change was calculated as the ratio 
between the mean percentage relative volume of the uterine 
leiomyoma and the normal myometrium.
Trypsin digestion and MALDI analysis. Spots from 2-DE were 
digested with sequencing grade‑modified trypsin (Promega 
Corporation, Madison, WI, USA) and analyzed by mass spec-
trometry (MS), as described by Ura et al (8).
The protein spots selected by 2-DE analysis were manually 
excised from the gels, washed with 50 mM NH4HCO3 and 
acetonitrile (ACN). After drying, 10 µl of trypsin (12.5 ng/µl 
in 50 mM NH4HCO3) were added to each gel piece and kept 
in ice for 30 min before being incubated overnight at 37˚C. 
Peptides were extracted from the gel pieces by three changes 
of 75% ACN/0.1% trifluoroacetic acid (TFA), dried under 
vacuum and then dissolved again in 10 µl of 0.1% TFA. 
One µl of each sample was mixed with 1 µl of (matrix 
α-cyano-4-hydroxycinnamic acid, 5 mg/ml in 70% ACN/0.1% 
TFA) and 0.8 µl of the final sample/matrix mixture were 
spotted onto a stainless steel MALDI target plate. Tandem 
mass spectrometry (MS/MS) analysis was performed on 
a MALDI-TOF/TOF 4800 mass spectrometer (AB Sciex, 
Framingham, MA, USA) in a data-dependent mode: A full MS 
scan was acquired, followed by MS/MS spectra of the 10 most 
intense signals.
Data were converted into Mascot generic format (MGF) 
files using the 4000 Series Explorer software (AB Sciex) and 
searched using Mascot search engine (version 2.4; Matrix 
Science, London, UK). Enzyme specificity was set to trypsin 
with one missed cleavage. Tolerance was set to 50 ppm and 
0.3 kDa for precursor and fragment ions respectively, and carb-
amidomethylation of cysteine was set as fixed modification, 
while methionine oxidation was set as variable modification. 
Proteins were considered as positively identified if ≥2 inde-
pendent peptides were identified with 95% confidence.
String network and functional analysis. The different expres-
sion proteins thus identified were analyzed by STRING 10.0 
(http://www.string-db.org/) for network generation and 
PANTHER 11.0 (Protein Analysis through Evolutionary 
Relationships; http://www.pantherdb.org) and Gene Ontology 
(http://amigo.geneontology.org/rte). Proteins were then classi-
fied according to their involvement in biological processes and 
pathways.
Western blotting. Western blot analysis was performed 
as previously described (12). Briefly, an equal amount of 
protein (30 µg) used for 2-DE analysis was separated by 
12% SDS-PAGE and then transferred to a nitrocellulose 
membrane. After being saturated by 5% defatted milk, 
membranes were incubated overnight at 4˚C with 1:1,000 
diluted primary rabbit polyclonal antibody against CALR, 
with 1:200 diluted primary rabbit polyclonal antibody 
against HSPA5, with 1:300 diluted primary rabbit poly-
clonal antibody against HSPB1, and with 1:700 diluted 
primary rabbit polyclonal antibody against HSPA1A. After 
washing, membranes were incubated with a HRP-conjugated 
anti-rabbit IgG (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) in a dilution of 1:3,000. The protein signal was 
visualized using SuperSignal West Pico Chemiluminescent 
substrate (Thermo Fisher Scientific Inc., Ottawa, ON, 
Canada). The intensities of the immunostained bands were 
normalized with the total protein intensities measured by 
Coomassie blue from the same blot.
Statistical analyses. For paired samples of both 2-DE and 
western blot data, statistical analyses were carried out with 
the non-parametric Wilcoxon sign-rank test. P<0.05 was 
considered to indicate a statistically significant difference. 
All statistical analyses were conducted with Stata/IC 14.2 for 
Windows (StataCorp LP, College Station, TX, USA).
Results
Proteomic studies. Comparative proteomic analysis was 
performed using 2-DE coupled with MS between uterine 
leiomyoma and myometrium tissues. Correlation analysis of 
gel‑pairs performed well, with average matching efficiency of 
approximately 75%. In this study, six protein spots belonging to 
chaperone proteins were found to be significantly dysregulated 
in leiomyoma samples if compared to the myometrium. Four 
spots were significantly upregulated (>1.5‑fold) and two were 
significantly downregulated (<0.6‑fold) (Fig. 1). These spots 
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corresponded to six proteins identified by MALDI‑TOF/TOF 
(Table I). Spot quantification revealed that the four proteins 
significantly upregulated in the leiomyoma if compared to the 
myometrium were CALR, HSPA5, PDIA3 and VCP, while the 
two downregulated proteins corresponded to HSPA1A and 
HSPB1.
These proteins are involved in the promotion of cell 
proliferation (CALR), in the negative regulation of apoptosis 
(HSPA5), protein folding (PDIA3, HSPB1), flavin adenine 
dinucleotide metabolic process (VCP) and protein complex 
assembly (HSPA1A). PANTHER pathway analysis locates 
these proteins in several pathways (p38 MAPK pathway, 
VEGF signaling pathway, UPR pathway) related to prolifera-
tion, migration and differentiation.
Immunohistochemical study of protein expression. In this 
study we validated the upregulated proteins CALR and HSPA5 
because the first is considered a marker of cell proliferation, 
while the second protects against apoptotic cell death, and 
could be associated with the promotion of leiomyoma growth. 
In addition, we also validated the two downregulated proteins 
HSPB1 and HSPA1A. The expression of CALR, HSPA5, 
HSPB1 and HSPA1A in five leiomyomas was compared to the 
expression in matched normal myometrial tissue (previously 
Figure 1. Two-dimensional electrophoresis map of normal myometrium and leiomyoma proteome. Immobilized pH gradient 3-10NL strips were used for the 
first dimension and 12% polyacrylamide gel was used for the second dimension. The numbered circles indicate the dysregulated chaperones.
Table I. Dysregulated chaperones identified by mass spectrometry in the leiomyoma and in the myometrium.
Accession Spot Protein Gene Sequence Fold- Biological
number number description symbol coverage % changea function Pathway
P27797 2 Calreticulin CALR 17.75 2.3 Positive regulation of UPR pathway
      cell proliferation 
P11021 3 78 kDa glucose- HSPA5 12.54 2 Negative regulation of Apoptosis
  regulated protein    apoptotic signaling signaling 
      pathway pathway
P30101 1 Protein disulfide‑ PDIA3 7.22 1.9 Protein folding UPR pathway
  isomerase A3
P55072 4 Transitional VCP 6.58 1.7 Flavin adenine UPR pathway
  endoplasmic reticulum    dinucleotide 
  ATPase    metabolic process
E7EP94 5 Heat shock 70 kDa HSPA1A 4.31 0.18 Protein complex Apoptosis
  protein 1A/1B    assembly signaling 
       pathway
P04792 6 Heat shock HSPB1 12.20 0.02 Protein folding p38 MAPK
  protein β-1     pathway
aFold‑change was defined as the ratio of the mean %V, according to the formula %V=(Vsingle spot)/(Vtotal spot) of uterine leiomyoma and 
normal myometrium. UPR, unfolded protein response; MAPK, mitogen-activated protein kinase.
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used in 2-DE analyis) samples by western blot analysis (Fig. 2). 
The five patients shown in the figure are representative of the 
total 15 patients included in the study, based on both 2-DE and 
western blotting expression of CALR, HSPA5 (both always up 
regulated), and HPA1A and HSPB1 (both always downregu-
lated).
CALR and HSPA5 expressions were significantly higher in 
the leiomyoma with respect to the myometrium, while HSPB1 
and HSPA1A were significantly downregulated, confirming 
results obtained from the 2-DE analysis. As previously 
described, for the normalization of immunostained bands, we 
used the total protein intensities because the two major gene 
housekeeping β-actin and tubulin were upregulated (9).
Protein‑protein interaction analysis. The chaperone proteins 
identified in this study were loaded to the STRING 10.0 
software for protein-protein interaction network based on 
confidence and molecular action prediction. The strongest 
interaction were between: CALR and PDIA3 (combined score, 
0.999), CALR and HSPA5 (combined score, 0.86), PDA3 and 
HSPA5 (combined score, 0.955), VCP and HSPA5 (combined 
score, 0.798) (Fig. 3A).
We further analyzed the interaction between MAPK1, 
BCL-2, AKT, ATF6, HSP90 (key proteins present in p38 
MAPK pathway, VEGF signaling pathway, UPR pathway) and 
the proteins identified in our study. An interesting result based 
on action prediction was the activation of CALR, HSPA5 by 
ATF and HSPA1A, HSPA5 by HSP90. Finally, the software 
predicted the post-translational modification of HSPB1 by 
AKT1 (Fig. 3B).
Discussion
Chaperones may play a key role in promoting cell survival (13). 
Several study have established that chaperone proteins play 
a fundamental role in the molecular mechanisms that lead 
to the emergence and progression of the tumor (14,15). At 
present it is clear that, within the tumor microenvironment, 
Figure 3. Prediction by STRING database. (A) Chaperones interaction on confidence prediction. (B) Chaperones and key proteins present in (p38 MAPK 
pathway, VEGF signaling pathway, UPR pathway) on molecular action prediction. For A, line thickness indicates the strength of data support. For B, line 
shape indicates the predicted mode of action, and colors indicate action types: Green, activation; red, inhibition; blue, binding; purple, catalysis; light blue, 
phenotype; fuchsia, posttranslational modification; black, reaction; yellow, transcriptional regulation.
Figure 2. Western blot analysis of HSPA5 CALR, HSP1A1, HSPB1 in paired myometrium (M) and leiomyoma (L). The intensity of immunostained bands was 
normalized against the total protein intensities measured from the same blot stained with Coomassie Blue. Number 1-5 indicate the patients. The bar graph 
shows the relative expression (band density) of HSPA5, CALR, HSP1A1, HSPB1 in the myometrium and the leiomyoma. Results are shown as a histogram 
(P<0.05) and each bar represents mean ± standard deviation.
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the increasing of chaperone activity induces a survival 
advantage on transformed cells over normal non-transformed 
cells (16).
To our knowledge, for the first time in this proteomics 
study we gathered data on the expression of several chaperones 
involved in cell proliferation and negative apoptosis regula-
tion, and we put them in relation with several key pathways of 
tumor development.
2-DE is a powerful method for quantitative comparative 
proteomic studies, capable of simultaneous resolution of thou-
sands of proteins, including isoforms or protein PTMs. Indeed, 
2-DE has been proven to have a quite high reproducibility even 
across different laboratories (17) and even below the cutoff of 
1.5-fold-change that was used in our study.
Leemer and colleagues (18) conducted an in-depth study 
on the proteomic profile of leiomyoma and myometrium 
samples by label-free GeLC-MS/MS, resulting in the identi-
fication and intensity‑based label‑free quantification of more 
than 7000 proteins. We compared our data with theirs. The 
expression of PDIA3, HSPA5, CALR, was confirmed to be 
upregulated, while the expression of HSPA1A and HSPB1 
was confirmed to be downregulated. The abundance of VLC 
was confirmed to be upregulated in the leiomyoma intersti-
tial fluid (8).
Calreticulin is a calcium-binding chaperone that promotes 
folding, oligomeric assembly and quality control in the 
endoplasmic reticulum (ER), promoting cell growth and 
proliferation in tumor prostate (19). Calreticulin overexpres-
sion is mediated via the activation of the ATF6 pathway in 
myeloid leukemic cells (20).
Overexpression of calreticulin promotes cell prolifera-
tion, inducing the upregulation of VEGF. This protein binds 
to specific receptors, activating signal pathways with a key 
role in cell proliferation, survival, migration, like MAPK 
(mitogen-activated protein kinase) and ERK (Ras/extracel-
lular signal regulated kinase) (21). This process could also 
be happening in the leiomyoma, where the overexpression of 
VEGF occurs (21).
HSPA5 is another calcium-binding chaperone playing an 
important role in maintaining cell viability against several 
kinds of stresses, including depletion of calcium from the 
endoplasmic reticulum (22). The overexpression of this protein 
in several tumors is induced by unfolded protein response.
HSPA5 protects tumor cells against apoptosis through 
various mechanisms: i) fighting protein aggregation in the 
ER; ii) binding Ca2+ and thus preventing calcium signaling in 
the cytosol; and iii) preventing the activation of pro-apoptotic 
components, such as BIK, BAX, pro-caspase 7 and pro-caspase 
12 (23).
Pressinotti et al confirmed the role of PDIA3 as a protein 
involved in the positive regulation of apoptosis in prostate 
cancer (24).
In this study we found HSPA1A and HSPB1 to be down-
regulated in the leiomyoma if compared to the myometrium. In 
our previous study (8) we identified HSPA1A as less abundant 
in the leiomyoma interstitial fluid, this being in line with our 
present data.
HSPB1 belongs to the group of small Hsps with 
anti-apoptotic and tumorigenic properties, and considered 
as important therapeutic targets, particularly in cancer 
pathology (25,26). Phosphorylation by MAP kinases and AKt 
underlies the modulation of the apoptosis by HSPB1 (27). Our 
STRING results support this finding.
PTEN is another enzyme that regulates HSPB1 activity, 
by acting as a protein tyrosine phosphatase. Downregulation 
of HspB1 upregulates PTEN levels and blocks the survival 
pathway of cancer cells (28). In the leiomyoma, PTEN is 
upregulated if compared to the myometrium (29), and this may 
be related to the downregulation of HSPB1 in the leiomyoma.
In conclusion, the 2-DE approach is a powerful approach 
for comparative proteomic analysis.
In our study we identified several dysregulated chaperones 
associated with cell proliferation and negative regulation of 
apoptosis. Although our proteins have been widely validated 
by western blotting, the absence of an immunohistological 
analysis is a limitation of the present study.
These proteins take part in several key pathways involved in 
tumor growth. In our opinion, functional studies are essential 
to understand the role of these chaperones in the leiomyoma, 
and thus to develop inhibitors and block tumor growth.
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